Acerta Pharma (ACP-196)
Aug 28, 2017
Bruton’s Tyrosine Kinase (BTK) Inhibitors An Emerging Therapeutic Target
Bruton's Tyrosine Kinase (BTK) is a cytoplasmic member from the Tec (tyrosine kinase expressed in hepatocellular carcinoma) group of kinases which is engaged with controlling the B cell expansion and is essential in B-lymphocyte advancement, separation, and signaling. Bruton's tyrosine kinase; also known as tyrosine...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
